Table 2. The comparison of FE-1 levels and SNAQ scores among the control and patients with CHF.
| Control (n = 20) |
NYHA I/II (n = 32) |
NYHA III (n = 42) |
NYHA IV (n = 30) |
||||
|---|---|---|---|---|---|---|---|
| FE-1 (μg/g stool) | 276.15±86.76 | 243.70±85.32 | a | 166.55±93.49 | a,b | 149.35±76.79 | a,b,c |
| FE-1 ≥ 200 (μg/g stool) n (%) | 0 (0.00%) | 24 (75.00%) | 13 (30.95%) | 8 (26.67%) | |||
| FE-1 ≥ 100 and < 200 (μg/g stool) n (%) | 0(0.00%) | 7 (21.88%) | a | 15 (35.71%) | a,b | 10 (33.33%) | a,b |
| FE-1 < 100 (μg/g stool) n (%) | 0 (0.00%) | 1 (3.13%) | 14 (33.33%) | 12 (40.00%) | |||
| SNAQ | 17.85±1.73 | 12.77±2.04 | a | 9.82±2.01 | a,b | 9.61±2.57 | a,b,c |
| SNAQ ≥14 | 20 (100.00%) | 22 (68.75%) | a | 9 (21.43%) | a,b | 3 (10.00%) | a,b |
| SNAQ<14 | 0 (0.00%) | 10 (31.25%) | 33 (78.57%) | 27 (90.00%) |
FE-1: Fecal elastase-1; SNAQ: the simplified nutritional appetite questionnaire; CHF: chronic heart failure; NYHA: New York Heart Association; Values expressed in mean±SD or frequency
aP<0.05: versus control
bP<0.05: versus NYHA I/II
cP<0.05: versus NYHA III.